Partner with DeepCovalent to turn target hypotheses into ranked, synthesis‑ready, and fully in-silico validated small molecules in ≤ 3 weeks using the OS3D™ — built to improve downstream success while reducing time and cost.
Accelerate Drug Discovery Together
Speed: Ideation to fully in-silico validated molecules ≤ 3 weeks.
Quality: Improved downstream success with multi‑objective optimization embeds potency, selectivity, ADMET, and developability constraints early.
Novelty: Unbiased accessing unexplored chemical space beyond incremental analog design.
Clarity: Transparent, partner‑friendly IP pathways and predictable collaboration structures.
Flexibility: In addition to the two core partnership models below, we remain open to customized collaboration structures that support unique scientific and strategic goals.
Why Partner with DeepCovalent
Partnership Models
On‑Demand Generation & Early Assessment
Rapid, low-cost access to OS3D™ to evaluate new or deprioritized targets.
Partners receive synthesis-ready and fully in-silico validated molecules in 3 weeks — enabling fast go/no-go decisions and early pipeline optionality with minimal risk.
A flexible, collaborative model with shared ownership of molecular IP. We focus on AI-driven molecular design and early discovery, while retaining the flexibility to extend into compound synthesis, preclinical validation, and IND-enabling studies under co-development agreements.